

**THE DEVELOPMENT OF A CANDIDATE TUBERCULOSIS
DNA VACCINE EXPRESSING Mtb8.4 and Ag85B of
*Mycobacterium tuberculosis***

by

MARYAM AZLAN

**Thesis submitted in fulfilment of the
requirements for the degree
of Master of Science**

February 2007

DEDICATIONS

This thesis is specially dedicated to:

My beloved husband, Ahmad Zarizi b. Shaari

My sons, Aiman Haris and Aiman Hakimi

My parents, Dr. Azlan and Dr. Kamariah

Thank you for your love, support and patience...

May God bless you all....

ACKNOWLEDGEMENTS

In the name of Allah, the most Generous and the most Merciful. All praise is due to Allah, for giving me inspiration and stoutheartedness along this journey.

During this research project, there are several people involved directly or indirectly whom I wish to acknowledge in this section.

I would like to thank my supervisor, Prof. Norazmi Mohd. Nor for his support, excellent guidance and supervision throughout the research project and also during the writing of this thesis. I wish to thank him for his trustee and confidence in me to carry out this project. His guidance is greatly appreciated.

I would like also to thank Assoc. Prof. Dr. Nik Soriani Yaacob, Prof. Zainul F. Zainuddin, Dr. Shaharum Shamsuddin and Dr. Rapeah Suppian who have provided advice, guidance, comments and helpful discussions during this study.

A special thanks to my friends and colleagues in the laboratory especially, Teo, Rohimah, Asma, Rafeezul, Boonyin, Kenny, Zila, Ayu, Syam and K. Rosilawani. Not to forget, my friends who are no longer in this group but have previously participated in contributing to my work, thank you to Halisa, Dr. Zul, K. Rozilawati, K. Nik Norliza, Arifin, Dr. Mohammed Abd. Aziz Sarhan, Dr. Fang Chee Mun and Wong Vic Cern. I would like to thank my friends in ZFZ and SS group, Eza, Abdah, Suwaibah, K. Salwana, Ayuni, Nurul, Zura, Aniek, Tini, Bad and Venugopal.

My deepest appreciation will be to my parents especially my beloved husband, Ahmad Zarizi for his greatest support, patience, love and encouragement. Thank you for always being there for me. My appreciation also goes to my beloved sons, Aiman Haris and Aiman Hakimi; their mischievousness had always cheered me. A special thanks to my parents, Dr. Azlan and Dr. Kamariah, my brother and sisters for their support and guidance during my work. I would like also to thank my parent in-law, Hj. Shaari and Pn. Noriah, my brothers and sister in-law for their understanding and support.

Finally, I would like to thank people who are directly or indirectly contributed to my work, in particular, Mr. Jamaruddin Mat Asan who provided technical assistance in flow cytometry handling, students and staff of PPSK, INFORMM and Microbiology department. I cannot mention you all here, so I hope you could feel my gratitude.

TABLE OF CONTENTS

	Page
	iii
ACKNOWLEDGEMENTS	
TABLE OF CONTENTS	v
LIST OF TABLES	x
LIST OF FIGURES	xi
LIST OF ABBREVIATION	xii
ABSTRACT	xiv
ABSTRAK	xv
 CHAPTER ONE: LITERATURE REVIEW	
 1.1 History of tuberculosis	1
1.2 Disease burden	2
1.3 <i>Mycobacterium tuberculosis</i> infection	4
1.4 Diagnosis	6
1.5 Symptoms and treatments	9
1.6 Immune response against TB	10
1.6.1 Macrophage	12
1.6.2 Cellular immune response	14
1.6.3 Humoral immune response	19
1.7 BCG - the current vaccine	21
1.7.1 Efficacy and effectiveness of BCG	22
1.7.2 Advantages of BCG	23
1.8 Candidate antigens of <i>M. tuberculosis</i>	24
1.8.1 Mtb8.4	24
1.8.2 Ag85B	24
1.9 Experimental vaccines developed against TB	25
1.9.1 DNA vaccine	26
1.9.1.1 Mechanisms of immune stimulation	26
1.9.1.2 Mechanisms of DNA vaccination	28
1.9.1.3 Advantages of DNA vaccination	33

1.9.2 Recombinant BCG expressing heterologous antigen	36
1.9.3 Prime-boost approach	39
1.10 Objectives of the study	42

CHAPTER TWO: MATERIALS AND METHODS

2.1 Materials	
2.1.1 Mycobacteria and <i>Eschericia coli</i> (<i>E. coli</i>) strains	44
2.1.2 Plasmids	44
2.1.3 Chemicals and reagents	44
2.1.4 Kits and consumables	44
2.1.5 Antibodies, enzymes and laboratory equipment	48
2.1.6 Mice	48
2.1.7 Sterilised, deionised distilled water	48
2.2 Preparation of media, buffers and solutions	
2.2.1 Luria-Bertani (LB) broth	48
2.2.2 Luria-Bertani agar (LA)	52
2.2.3 7H9 broth	52
2.2.4 RPMI media	52
2.2.5 Kanamycin stock solution (50mg/ml)	52
2.2.6 Ampicillin stock solution (50mg/ml)	53
2.2.7 Magnesium chloride (MgCl ₂) solution (100mM)	53
2.2.8 Calcium chloride (CaCl ₂) solution (100mM)	53
2.2.9 Glycerol solution (80%)	53
2.2.10 Ethanol solution (70%)	54
2.2.11 Hydrochloride solution (HCl) solution (1M)	54
2.2.12 Sodium hydroxide (NaOH) solution (3M)	54
2.2.13 Ethylene diamine tetraacetic acid (EDTA) solution(0.5M)	54
2.2.14 Tris-EDTA (TE) buffer	54
2.2.15 Tris-acetate-EDTA (TAE) solution	55
2.2.16 Loading dye solution	55
2.2.17 DNA marker	55
2.2.18 Ethidium bromide solution	55
2.2.19 Isopropyl-D-thiogalactopyranoside (IPTG) (1 M)	55

2.2.20	Tris-base (1.5M) containing 0.4% SDS	56
2.2.21	Tris-HCl (1.5M) containing 0.4% SDS	56
2.2.22	Resolving buffer	56
2.2.23	Stacking buffer	56
2.2.24	Ammonium persulfate solution (20%)	56
2.2.25	SDS-PAGE running buffer	57
2.2.26	Sample buffer	57
2.2.27	Coomassie blue solution	57
2.2.28	Destaining solution	57
2.2.29	Towbin transfer buffer	58
2.2.30	Blocking solution (5%)	58
2.2.31	Phosphate buffered saline (PBS) (10X)	58
2.2.32	PBS-Tween 20 (PBS-T20)	58
2.2.33	Washing buffer (Buffer C)	58
2.2.34	Elution buffer (Buffer D & Buffer E)	59
2.2.35	Dialysis buffer	59
2.2.36	[methyl- ³ H] Thymidine solution	59
2.2.37	Trypan blue solution (0.4%)	59
2.2.38	Staining buffer for flow cytometry	60
2.2.39	Ammonium chloride / potassium (ACK) lysis solution	60
2.2.40	Coating buffer for ELISA	60
2.2.41	Blocking buffer for ELISA	60
2.2.42	ABTS substrate	61
2.2.43	Stop solution	61
2.3	Methods	
2.3.1	Preparation of <i>E. coli</i> competent cells	61
2.3.2	Transformation of competent <i>E. coli</i> cells	62
2.3.3	Glycerol stock of <i>E. coli</i>	62
2.3.4	BCG and recombinant BCG (rBCG) culture	63
2.3.5	Preparation for Polymerase chain reaction (PCR)	
2.3.5.1	Preparation of oligonucleotides working solution	63
2.3.5.2	Preparation of primer working solution	64
2.3.5.3	Preparation of 'master mix' for PCR	64
2.3.6	Assembly PCR	64

2.3.7 DNA agarose gel electrophoresis	65
2.3.7.1 Preparation of agarose gel	65
2.3.7.2 Separation of DNA on agarose gel electrophoresis	65
2.3.8 Extraction of plasmid DNA	66
2.3.9 DNA extraction from agarose gel	67
2.3.10 DNA purification	67
2.3.11 Plasmid extraction for removal of endotoxin	68
2.3.12 Restriction enzyme (RE) digestion	69
2.3.13 Quantification of DNA	70
2.3.14 DNA Ligation	70
2.3.15 Protein analysis	70
2.3.15.1 Expression of Mtb8.4 in <i>E. coli</i>	70
2.3.15.2 Preparation of resolving gel (10%)	71
2.3.15.3 Preparation of stacking gel (4.5%)	71
2.3.15.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)	72
2.3.15.5 Western blotting	72
2.3.15.6 Quantification of protein concentration	73
2.3.15.7 Purification of 6XHis-tagged protein	74
2.3.15.8 Dialysis of purified protein	74
2.3.16 Immunogenicity studies	
2.3.16.1 Immunization procedure	75
2.3.16.2 Collection of sera	77
2.3.16.3 Splenocyte preparation	77
2.3.16.4 Cell culture	78
2.3.16.5 Cell surface and intracellular cytokine assay	78
2.3.16.6 Proliferation assay	79
2.3.16.7 Enzyme-linked immunosorbent assay (ELISA)	80

CHAPTER THREE: RESULTS

3.1 Introduction	81
3.2 Construction of the DNA vaccine, pNMN023	84

3.3	Purification of Mtb8.4	84
3.4	Immunogenicity studies	89
3.4.1	DNA vaccine	89
3.4.1.1	Proliferation assay of mice splenocytes immunized with DNA vaccine	89
3.4.1.2	Antibody response of mice immunized with DNA vaccine	89
3.4.1.3	Detection of intracellular cytokines produced by CD4 ⁺ T cells and CD8 ⁺ T cells from splenocytes of mice immunized with pNMN023	91
3.4.2	Prime-boost approach	101
3.4.2.1	Antibody response of mice immunized with the prime-boost approach	101
3.4.2.2	Detection of intracellular cytokines produced by CD4 ⁺ T cells and CD8 ⁺ T cells from splenocytes of mice immunized with the prime-boost approach	101
CHAPTER FOUR: GENERAL DISCUSSION		109
BIBLIOGRAPHY		119
APPENDICES		139

LIST OF TABLES

		Page
Table 1.1	Comparative analysis of various vaccine formulations	34
Table 1.2	rBCG as vaccine candidates	37
Table 2.1	List of general chemicals and reagents	45
Table 2.2	List of kits and consumables	47
Table 2.3	List of antibodies	49
Table 2.4	List of enzymes	50
Table 2.5	List of equipment	51
Table 2.6	Immunization schedules of the DNA vaccine and the prime-boost approach	76
Table 3.1	List of peptides for stimulation of splenocytes	90
Table 3.2	Classification of responses based on the increase in the percentage of cells expressing selected intracellular cytokines by flow cytometry	95
Table 3.3	Summary of the percentage of cells expressing cytokines as determined by flow cytometry and the SI of cells in the proliferation assay	100
Table 3.4	Summary of the percentage of cells expressing selected cytokines following immunizations with the prime-boost approach	106

LIST OF FIGURES

		Page
Figure 1.1	Tuberculosis notification rates, 2004	3
Figure 1.2	Outcomes associated with exposure to <i>M. tuberculosis</i>	5
Figure 1.3	AFB smear	7
Figure 1.4	Four stages of pulmonary TB	11
Figure 1.5	CD4 ⁺ T helper lymphocyte subsets upon activation	15
Figure 1.6	Pathways associated with MHC class I	27
Figure 1.7	Mechanisms of DNA vaccination	29
Figure 1.8	Prime-boost vaccination strategies	40
Figure 1.9	Flowchart of the study	43
Figure 3.1	Amino acid sequence of TB 1.0 fragment	82
Figure 3.2	pVAX1 Plasmid map	83
Figure 3.3	Agarose gel electrophoresis of assembly PCR	85
Figure 3.4	Schematic diagram of the construction of pNMN023	86
Figure 3.5	pPROExHTa™ and pNMN022 plasmid map	87
Figure 3.6	SDS-PAGE and Western blot analyses	88
Figure 3.7	Mean OD of total serum IgG in mice (DNA vaccine)	92
Figure 3.8	Mean OD of IgG subclasses in mice (DNA vaccine)	93
Figure 3.9	Examples of flow cytometry profiles	94
Figure 3.10	Percentage of CD4 ⁺ and CD8 ⁺ expressing IL-2 (DNA vaccine)	97
Figure 3.11	Percentage of CD4 ⁺ and CD8 ⁺ expressing IL-4 (DNA vaccine)	98
Figure 3.12	Percentage of CD4 ⁺ and CD8 ⁺ expressing IFN- γ (DNA vaccine)	99
Figure 3.13	Mean OD of total serum IgG in mice (Prime-boost)	102
Figure 3.14	Mean OD of IgG subclasses in mice (Prime-boost)	104

LIST OF ABBREVIATIONS

AFB	Acid fast bacillus
$\alpha\beta$	Alpha beta
Ag85	Antigen 85
APCs	Antigen presenting cells
BCG	Bacille Calmette Guerin
β 2-m	Beta-2-microglobulin
CMI	Cell mediated immunity
CFU	Colony forming unit
CTL	Cytotoxic T lymphocyte
ddH ₂ O	Deionised distilled water
DTH	Delayed type hypersensitivity
DCs	Dendritic cells
DNA	Deoxyribonucleic acid
ER	Endoplasmic reticulum
$\gamma\delta$	Gamma delta
HIV	Human Immunodeficiency Virus
HLA	Human leukocyte antigen
IFN	Interferon
IL	Interleukin
i.m	Intramuscular
i.p	Intraperitoneal
kDa	kilodalton
KO	Knock-out
LB	Luria-bertani
MHC	Major histocompatibility complex
mAbs	Monoclonal antibodies
MDR-TB	Multi drug resistant TB
NAA	Nucleic acid amplification
NK	Natural killer
Nramp	Natural-resistance-associated macrophage protein
O.D	Optical density
PBMC	Peripheral blood mononuclear cell

PCR	Polymerase chain reaction
PPD	Purified protein derivative
rBCG	Recombinant bacille Calmette Guerin
RNI	Reactive nitrogen intermediates
ROI	Reactive oxygen intermediates
RD	Region of difference
RE	Restriction enzyme
SIV	Simian immunodeficiency virus
SI	Stimulation index
Th	T helper
TAP	Transporter associated protein
TB	Tuberculosis
TNF	Tumor necrosis factor
UV	Ultraviolet
WHO	World Health Organization

THE DEVELOPMENT OF A CANDIDATE TUBERCULOSIS DNA VACCINE EXPRESSING Mtb8.4 and Ag85B of *Mycobacterium tuberculosis*

ABSTRACT

Tuberculosis (TB) is still one of the major health problems worldwide. The only TB vaccine currently available is an attenuated strain of *Mycobacterium bovis*, bacille Calmette Guerin (BCG). However, the efficacy of BCG vaccine continues to be debated. Therefore, a more effective vaccine against TB is urgently needed. DNA vaccination is a new approach to the control of infectious agents. In this study, a DNA vaccine encoding the candidate TB antigens Mtb8.4 and Ag85B was developed using assembly PCR. Balb/c mice were immunized intramuscularly with 50 µg of the DNA vaccine, pNMN023, containing the two antigens, in each hindleg. Reactivity against the Ag85B peptides, P1 and P3 as well as Mtb8.4 showed a consistent Th1 type of immune response by virtue of the increased expression of IL-2, IFN-γ and IgG2a. Splenocytes from immunized mice were also found to proliferate more aggressively when stimulated with the antigens compared to the vector alone. In order to improve the vaccine efficacy, a preliminary prime-boost approach was used. Priming with pNMN023 and boosting with recombinant BCG (rBCG) in Balb/c mice was carried out. Flow cytometric intracellular cytokine analyses of splenocytes from mice immunized with the DNA-rBCG prime-boost regime showed that both CD4⁺ and CD8⁺ T cells showed an increase in IL-2 and IFN-γ production following stimulation with either antigens at significantly higher levels than those immunized with rBCG-DNA prime-boost. In conclusion, the data obtained from this study suggest that DNA vaccination in combination with the prime-boost approach provide a potential strategy for developing a candidate vaccine against TB.

**PEMBANGUNAN CALON DNA VAKSIN TERHADAP TUBERKULOSIS YANG
MENGEKSPRESKAN Mtb8.4 DAN Ag85B DARIPADA
*Mycobacterium tuberculosis***

ABSTRAK

Tuberkulosis (TB) merupakan salah satu penyakit utama di dunia. Satu-satunya vaksin TB yang terdapat pada masa ini ialah strain yang telah dilemahkan iaitu, *Mycobacterium bovis* bacille Calmette-Guerin (BCG). Bagaimanapun, keberkesanan BCG masih diperdebatkan. Oleh itu, vaksin yang lebih efektif terhadap TB sangat diperlukan. Vaksin DNA merupakan salah satu cara untuk mengawal ejen infeksi. Di dalam kajian ini, vaksin DNA yang mengkodkan antigen TB iaitu, antigen Mtb8.4 dan antigen Ag85B telah dibangunkan menggunakan kaedah PCR himpunan. Mencit Balb/c telah diimmunisasi intraotot dengan 50 µg vaksin DNA, pNMN023, yang mengandungi kedua-dua antigen. Kereaktifan terhadap peptida Ag85B, P1 dan P3 juga Mtb8.4 telah menunjukkan peningkatan tindakbalas imun jenis Th1 yang konsisten melalui peningkatan pengekspresian IL-2, IFN-γ dan IgG2a. Splenosit dari mencit yang diimmunisasi juga didapati menunjukkan peningkatan gerak balas proliferasi apabila dirangsang dengan kedua-dua antigen. Untuk meningkatkan keberkesanan vaksin, kajian awal menggunakan pendekatan 'prime-boost' telah digunakan. 'Priming' dengan pNMN023 dan 'boosting' dengan BCG rekombinan (rBCG) di dalam mencit Balb/c telah dijalankan. Analisis intrasel sitokin dari splenosit mencit yang telah diimmunisasi dengan DNA-rBCG menunjukkan peningkatan IL-2 dan IFN-γ kedua-dua sel T CD4⁺ dan CD8⁺ apabila dirangsang dengan kedua-dua antigen berbanding mencit yang diimmunisasi dengan rBCG-DNA. Sebagai kesimpulan, data yang diperolehi dari kajian ini mencadangkan bahawa vaksin DNA digabungkan dengan kaedah 'prime-boost' merupakan salah satu kaedah yang berpotensi untuk membangunkan calon vaksin terhadap TB.

CHAPTER 1

LITERATURE REVIEW

1.1 History of tuberculosis

Tuberculosis (TB) in humans is caused by *Mycobacterium tuberculosis* while *M. bovis* causes TB infection in cattle. The Hippocratic Collection compiled around 400 - 350 B.C. recorded the clinical manifestations and epidemiologic features of phthisis (Greek term), the tuberculous process in the lungs was called a 'phyma' (Iseman, 2000). The frequency of unearthed skeletons with apparent tubercular deformities in ancient Egypt suggests that the disease was common among that population. Evidence of bone lesions suggestive of TB in mummies of North America and Egypt confirms the ancient impact of this disease on early civilizations (Nerlich *et al.*, 2000; Rothschild *et al.*, 2001) and further confirmed by the use of molecular-based diagnosis of TB in some ancient Egyptian mummies (reviewed by Bedeir, 2004).

During the golden age of Islam, Ibnu Sina described the clinical features and pathology of TB in Arabic scripts (reviewed by Madkour *et al.*, 2004). The discovery of similarly deformed bones in various Neolithic sites in Italy, Denmark, and countries in the Middle East also indicates that TB was found throughout the world approximately 4,000 years ago.

In the 18th century, TB was well established in Europe and had spread to Africa, Asia, South America and Eastern Europe by the end of the 19th century. In 1882, Robert Koch discovered tubercle bacillus as the causative agent of TB. In 1993, due to the emergence of TB incidence worldwide, TB was declared as a 'global emergency' by the World Health

Organization (WHO) and a decade later, the first international conference on 'TB vaccine for the world' was held in Montreal.

1.2 Disease burden

It is estimated that two billion people (one third of the world's population) is infected with *M. tuberculosis* (WHO, 2001), where 8.8 million people will show clinical diseases and 1.5 million will die every year (WHO, 2004). TB also occurs in Southeast Asia with three million new cases every year and a quarter of a million in Eastern Europe (Girard *et al.*, 2005). These situations are worsened with the estimation that only 40% of new cases of pulmonary TB are currently detected (Dye *et al.*, 2002). If controlling efforts are not accelerated, 10 million new TB cases are expected in 2010 (Dye, 2000).

Rising rates of drug-resistant TB have contributed to worsen treatment outcomes in some regions (Figure 1.1). The incidence of TB increased in areas with high rates of human immunodeficiency virus (HIV) infection. Approximately, 14 million people are co-infected with *M. tuberculosis* and HIV, including more than 70% of those living in some regions of sub-Saharan Africa (WHO, 2004).

An initiative to address the increase of TB disease burden known as "Stop TB" was created in 1998 to ensure that endemic countries are adequately supported by technically and financially to control TB (Raviglione & Pio, 2002). Among the supports include the US National Institute for Allergy and Infectious Diseases (NIAID), the Aeras Global TB Vaccine Foundation, the European Union Commission and pharmaceutical manufacturers including GlaxoSmithKline (GSK) and IDRI-Corixa (Hewinson, 2005).




Figure 1.1: Tuberculosis notification rates, 2004. (Adapted from WHO report 2006)

1.3 *Mycobacterium tuberculosis* infection

M. tuberculosis belongs to the Mycobacteriaceae family and Actinomycetales order. Humans are the only reservoirs. *M. tuberculosis* is an aerobic, non-spore forming, non-motile, slightly curved or straight rod bacterium of 0.2 - 0.6 X 1.0 - 10 µm in length. The cell wall of *M. tuberculosis* contains high content of complex lipids. One of the components is mycolyl-arabinogalactan which acts as a hydrophobic permeability barrier that prevents penetration of common aniline dyes.

TB is spread through the air from one person to another. Primary infection begins upon inhalation of 1-10 aerosolized bacilli. The bacteria can settle in the lungs and begin to grow. From there, they can move through the blood to other parts of the body, such as the kidney, spine, and brain. This pathogenic mycobacteria can survive in the hostile habitat of the macrophage, the main immune cell that attract the bacilli. Following the infection of *M. tuberculosis*, 30% of individuals will become infected, with about 40% of these individuals develop primary active TB while the remaining 60% develop latent infection (Figure 1.2). Latent infection is described as a clinical syndrome that occurs after an individual has been exposed to *M. tuberculosis*. During that particular stage, the immune response has been generated to control the pathogen and force it into a dormant stage. Individuals with latent TB do not transmit the disease. After years of dormancy, this organism may start to replicate, leading to reactivation of infection and clinical disease. Individual who is latently infected, can develop active disease via either endogenous reactivation of the latent bacilli or exogenous reinfection with a second mycobacterial strain. Approximately, 2 - 23% of immunocompetent patients with latent TB will reactivate at a later date, while patients with HIV develop reactivation of TB at a rate of 5 - 10% per year (Figure 1.2) due to progressive depletion and dysfunction of the macrophage (Goletti *et al.*, 1996).




Figure 1.2: Outcomes associated with exposure to *M. tuberculosis*. (Adapted from Parrish *et al.*, 1998).

The capacity to limit the proliferation of tubercle bacilli within macrophage resides largely with CD4⁺ T-helper (Th) lymphocytes. Despite HIV patients, the reactivation of the pathogen will most probably occur in people with immunosuppression due to age, corticosteroids and malnutrition (Flynn, 2004).

The pathogenicity of the organism is determined by its ability to escape the host immune response as well as eliciting delayed type hypersensitivity (DTH). DTH is used as a general category to describe all those hypersensitivity reactions that take more than 12 hours to develop, which involve cell-mediated immune (CMI) reactions rather than humoral immune reactions. DTH skin testing or Mantoux reaction is carried out to determine previous exposure to TB by injection of tuberculin into the skin of an individual in whom previous infection with the mycobacterium had induced a state of CMI. The reaction is characterized by erythema and induration which appears only after several hours and reaches a maximum at 24 - 48 hours.

1.4 Diagnosis

The most common method used to diagnose TB is by smear microscopy or known as Acid-fast bacillus (AFB) shown in Figure 1.3 which is the most popular, rapid and inexpensive method. However, the reliability of this method is highly dependent on the experience of the laboratory personnel and on the number of organisms present in the specimen. Another method known as the current 'gold standard' is by culture whether on solid or liquid media.

One of the latest technologies used to diagnose TB is by nucleic acid amplification (NAA)-based assays. NAA refers to a technique in which the nucleic acid (DNA or RNA) of an



Figure 1.3: AFB smear

organism is amplified by as much as 40 orders of magnitude, after which a probe detects a target sequence of DNA or RNA unique to a particular organism. Compared to smear and culture technique, sensitivity and specificity of NAA are usually very high (Pfyffer, 1999) and can detect as few as 10 organisms in 1 ml of clinical sample (Schluger & Rom, 1995). NAA method can also reduce the diagnostic time from weeks to days. Currently, two NAA methods are available commercially, the Enhanced *Mycobacterium tuberculosis* Direct Test (Gen-Probe®) and the Amplicor® *Mycobacterium tuberculosis* Test (Roche Diagnostic Systems) (reviewed by Soini & Musser, 2001). Both products have been approved by the Food and Drug Administration USA (FDA) in 1999 for direct detection of *M. tuberculosis* from clinical specimens (CDC, 2000). The NAA test can enhance diagnostic speed, but could not replace AFB smear or culture because the test cannot distinguish between live and dead organisms. In addition, NAA test require complex equipment as well as highly technical staff. Therefore, clinicians should interpret the NAA test results based on the clinical situation and the test should be performed at the request of the clinician (Soini & Musser, 2001).

Besides the AFB, culture and NAA methods of TB diagnosis, susceptibility testing is one of the available alternatives if the culture remains positive over a longer period of time. Drug susceptibility testing is mandatory on initial isolates of *M. tuberculosis* and related species from all patients. Susceptibility testing is conducted to monitor a possible development of drug resistance. Conventional method for drug susceptibility is by testing on solid media (Middlebrook 7H11 or LJ). Another recent method of drug susceptibility testing is by radiometric liquid culture system (BACTEC) which provides a vial containing a substance [para-nitro-alpha-acetylamine-hydroxypropiophenone (NAP)], which selectively suppress the growth of *M. tuberculosis* complex species. Among members of the *M. tuberculosis* complex are *M. tuberculosis*, *M. bovis*, *M. africanum* and *M. microtii*. Each member of the

M. tuberculosis complex is pathogenic. If a subculture from the initial vial fails to demonstrate growth in the NAP, that is presumptive evidence for a species within *M. tuberculosis* complex.

1.5 Symptoms and treatments

The symptoms of TB depend on the site where the bacteria are growing whether in pulmonary or extrapulmonary. In the lungs, symptoms such as coughing for 3 weeks or longer, pain in the chest and coughing out blood or sputum are very common. Only active TB patients will show some other possible symptoms which are; weakness or fatigue, weight loss, fever, sweating at night and reduced appetite. Besides pulmonary TB, most extrapulmonary forms of TB includes; TB meningitis, tuberculous lymphadenitis, pericardial TB, pleural TB and disseminated or miliary TB. People with HIV, infants and young children seem to have an increased risk for extrapulmonary TB.

Containment of TB has been carried out by the WHO-recommended “directly observed treatment short course” (DOTS) strategy. This treatment involves TB patients observed taking every single dose drug for the first 2 month of the 6 to 8 month treatment regimens. More than 17 million patients benefited from the DOTS strategy, but in some cases multi-drug resistant TB (MDR-TB) occurs when the treatment is incomplete (Girard *et al.*, 2005). MDR-TB is defined as strains of *M. tuberculosis* resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs. The first documented case of MDR-TB was in a lung transplant patient in 1999 (Lee *et al.*, 2003). Transplant patients are chronically immunosuppressed and in that study, the donated lungs were from a recent Chinese immigrant who was at high-risk for previous exposure. Fortunately, fluctuations and variations of isoniazid, rifampicin, pyrazinamide and rifabutin were successful in saving the patient.

1.6 Immune response against TB

Immune response involved in TB infection is complex. The components involved are T cells ($CD4^+$ and $CD8^+$), cytokines (IFN- γ , TNF- α , IL-12 and IL-6) and macrophages (Flynn, 2004). The immune response may also differ in acute and chronic infection. Four stages of pulmonary TB (Figure 1.4) have been reviewed by van Crevel *et al.* (2002). The first stage is the inhalation of tubercle bacilli. After an incubation period of 4 to 12 weeks, alveolar macrophage will ingest the bacilli and destroy them. These depend on the intrinsic microbicidal capacity of host phagocytes as well as the virulence factors of the ingested mycobacteria.

Mycobacteria which escape the first stage will enter the second stage where three scenarios could occur. The first scenario is when the host failed to contain the pathogen and die. Secondly, the mycobacteria may spread throughout the body when the host immune response is weak (normally occurs in immunocompromised patients) causing active disease. The third scenario is when the host immune response and the virulence of *M. tuberculosis* are balanced and the intracellular bacteria are contained within the macrophage. Macrophage disruption will attract blood monocytes and other inflammatory cells to the lungs. Monocytes will differentiate into macrophages and ingest the mycobacteria but will not destroy them. Little tissue damage occurs at this stage. T cell immunity will develop after 2 to 3 weeks of infection, leading to proliferation of antigen specific T lymphocytes within the early lesions. Host immune system isolates the primary site of infection by granuloma formation. The granuloma contains lymphocytes including $CD4^+$ and $CD8^+$ T cells as well as B cells. In addition, fibroblasts and other cells can be present within the granuloma (Co *et al.*, 2004). The granuloma functions to limit the spread




Figure 1.4: Four stages of pulmonary TB (Modified from Kaufmann & Ulrichs, 2003)

of the infection by walling off the organisms from the rest of the lung, prevents metastasis of the infection and providing an environment for the action of the immune components (Salgame, 2005).

During the third stage of pulmonary infection, the early bacilli growth will stop (Ulrichs & Kaufmann, 2003). Solid necrosis in the primary lesions will inhibit extracellular growth of mycobacteria and the infection may become dormant for months or years. During the final stage, any disturbance of the balance between the host and pathogen after weakening of the cellular immune response causes endogenous exacerbation which leads to active TB. Cavity formation may lead to rupture of nearby bronchi, causing the bacilli to spread to other parts of the lungs or host's organ.

1.6.1 Macrophage

Macrophage has been identified as the key immune cell for the control of *M. tuberculosis* infection. The organism can multiply within resting macrophage but become inhibited when the macrophage is activated. Cytokines including IFN- γ and TNF- α and also vitamin D involves in macrophage activation (van Crevel *et al.*, 2002). Following inhalation of mycobacteria droplets, *M. tuberculosis* is engulfed by alveolar macrophages. The interaction between macrophages and mycobacteria involves a variety of host cell receptors including Fc receptors (FcR), complement receptors (CR), macrophage mannose receptor (MMR) and also Toll-like receptor 2 (TLR-2) and TLR-4.

Macrophage plays multiple roles in TB including antigen processing and presentation, effector cell function and also apoptosis (Silva *et al.*, 2001). Apoptosis of phagocytic cells may prevent dissemination of infection and reduces viability of intracellular mycobacteria. Klinger and colleagues (1997) have demonstrated that apoptosis associated with TB is

mediated through a downregulation of bcl-2, an inhibitor of programmed cell death. The activated macrophage produces reactive oxygen intermediates (ROIs) by oxidative burst and reactive nitrogen intermediates (RNIs) via inducible nitric oxide synthase (iNOS2). Cooper *et al.* (2000) provided evidence that ROI-mediated control is important during early infection by the observation of a 10-fold higher bacterial numbers in the lungs of p47phox knockout (KO) mice, compared to wild-type controls, after aerosol challenge with *M. tuberculosis*. The p47phox is a phagosome oxidase component critical for the activity or assembly of the functional oxidase. RNIs are the critical effector molecules against *M. tuberculosis* in the mouse. Moreover, mice deficient in NOS2 activity are very susceptible to acute or chronic *M. tuberculosis* infection compared to wild-type mice (MacMicking *et al.*, 1997; Scanga *et al.*, 2001).

Macrophage activation also involves natural-resistance-associated macrophage protein (*Nramp1*) gene and vitamin D. *Nramp1* is an interesting gene involved in macrophage activation and mycobacterial killing (Blackwell *et al.*, 2000). The protein is an integral membrane protein which belongs to a family of metal ion transporters. These metal ions, particularly Fe^{2+} , are involved in macrophage activation and generation of toxic antimicrobial radicals (Zwilling *et al.*, 1999). Following phagocytosis, *Nramp1* becomes part of the phagosome. *Nramp1* mutant mice display reduced phagosomal maturation and acidification (Hackam *et al.*, 1998).

Macrophage suppresses the growth of *M. tuberculosis* by the helps of active metabolite of vitamin D, 1, 25-dihydroxyvitamin D (Rockett *et al.*, 1998). A recent study among Gujarati Hindus, a mainly vegetarian immigrant population in London, showed that vitamin D deficiency was a risk factor for TB (Wilkinson *et al.*, 2000). Eventhough activated macrophage can sometimes kill virulent *M. tuberculosis* (Sato *et al.*, 1998) but it is

generally cannot eliminate the infection entirely. Therefore, other components of the immune system including cellular and humoral immune responses participate to eliminate the mycobacteria.

1.6.2 Cellular Immune Response

Van Crevel *et al.* (2002) has discussed three processes that contribute to the initiation of cellular immune response against TB; antigen presentation, costimulation and cytokine production. Antigen presentation involves CD4⁺ T cells, CD8⁺ T cells and unconventional T cells including CD1 and $\gamma\delta$ T cells. In general, CD4⁺ T cells help to amplify the host immune response by activating effector cells and recruiting additional immune cells to the site of disease, whereas CD8⁺ T cells are important during the latent stage of TB infection, which act as cytotoxic T cells (CTL) by lysing infected cells (Schluger & Rom, 1998) through production of various cytokines such as IFN- γ and TNF- α . Within a week of infection with virulent *M. tuberculosis*, the number of activated CD4⁺ and CD8⁺ T cells in the lung-draining lymph nodes increases (Feng *et al.*, 1999; Serbina *et al.*, 2000).

Basically, CD4⁺ Th lymphocytes differentiate from precursor Th0 cells under the control of cytokines such as IL-2 and IL-4 into two functionally distinct subsets either type 1 (Th1) or type 2 (Th2) cells (Figure 1.5). Th1 secretes cytokines such as IL-2, IFN- γ , TNF- α and IL-12 resulting in macrophage activation and induction of CMI. In contrast, Th2 secretes IL-4, IL-5, IL-6 and IL-10 resulting in the induction of humoral immunity by antibody production. *M. tuberculosis* resides primarily in a vacuole within the macrophage resulting in major histocompatibility complex (MHC) Class II presentation of mycobacterial antigens to CD4⁺ T cells. The HIV epidemic has demonstrated that the loss of CD4⁺ T cells greatly increases susceptibility of the host to both acute and reactivation TB (reviewed by Flynn, 2004).

of the infection by walling off the organisms from the rest of the lung, prevents metastasis of the infection and providing an environment for the action of the immune components (Salgame, 2005).

During the third stage of pulmonary infection, the early bacilli growth will stop (Ulrichs & Kaufmann, 2003). Solid necrosis in the primary lesions will inhibit extracellular growth of mycobacteria and the infection may become dormant for months or years. During the final stage, any disturbance of the balance between the host and pathogen after weakening of the cellular immune response causes endogenous exacerbation which leads to active TB. Cavity formation may lead to rupture of nearby bronchi, causing the bacilli to spread to other parts of the lungs or host's organ.

1.6.2 Macrophage

Macrophage has been identified as the key immune cell for the control of *M. tuberculosis* infection. The organism can multiply within resting macrophage but become inhibited when the macrophage is activated. Cytokines including IFN- γ and TNF- α and also vitamin D involves in macrophage activation (van Crevel *et al.*, 2002). Following inhalation of mycobacteria droplets, *M. tuberculosis* is engulfed by alveolar macrophages. The interaction between macrophages and mycobacteria involves a variety of host cell receptors including Fc receptors (FcR), complement receptors (CR), macrophage mannose receptor (MMR) and also Toll-like receptor 2 (TLR-2) and TLR-4.

Macrophage plays multiple roles in TB including antigen processing and presentation, effector cell function and also apoptosis (Silva *et al.*, 2001). Apoptosis of phagocytic cells may prevent dissemination of infection and reduces viability of intracellular mycobacteria. Klinger and colleagues (1997) have demonstrated that apoptosis associated with TB is

mediated through a downregulation of bcl-2, an inhibitor of programmed cell death. The activated macrophage produces reactive oxygen intermediates (ROIs) by oxidative burst and reactive nitrogen intermediates (RNIs) via inducible nitric oxide synthase (iNOS2). Cooper *et al.* (2000) provided evidence that ROI-mediated control is important during early infection by the observation of a 10-fold higher bacterial numbers in the lungs of p47phox knockout (KO) mice, compared to wild-type controls, after aerosol challenge with *M. tuberculosis*. The p47phox is a phagosome oxidase component critical for the activity or assembly of the functional oxidase. RNIs are the critical effector molecules against *M. tuberculosis* in the mouse. Moreover, mice deficient in NOS2 activity are very susceptible to acute or chronic *M. tuberculosis* infection compared to wild-type mice (MacMicking *et al.*, 1997; Scanga *et al.*, 2001).

Macrophage activation also involves natural-resistance-associated macrophage protein (*Nramp1*) gene and vitamin D. *Nramp1* is an interesting gene involved in macrophage activation and mycobacterial killing (Blackwell *et al.*, 2000). The protein is an integral membrane protein which belongs to a family of metal ion transporters. These metal ions, particularly Fe^{2+} , are involved in macrophage activation and generation of toxic antimicrobial radicals (Zwilling *et al.*, 1999). Following phagocytosis, *Nramp1* becomes part of the phagosome. *Nramp1* mutant mice display reduced phagosomal maturation and acidification (Hackam *et al.*, 1998).

Macrophage suppresses the growth of *M. tuberculosis* by the helps of active metabolite of vitamin D, 1, 25-dihydroxyvitamin D (Rockett *et al.*, 1998). A recent study among Gujarati Hindus, a mainly vegetarian immigrant population in London, showed that vitamin D deficiency was a risk factor for TB (Wilkinson *et al.*, 2000). Eventhough activated macrophage can sometimes kill virulent *M. tuberculosis* (Sato *et al.*, 1998) but it is

generally cannot eliminate the infection entirely. Therefore, other components of the immune system including cellular and humoral immune responses participate to eliminate the mycobacteria.

1.6.2 Cellular Immune Response

Van Crevel *et al.* (2002) has discussed three processes that contribute to the initiation of cellular immune response against TB; antigen presentation, costimulation and cytokine production. Antigen presentation involves CD4⁺ T cells, CD8⁺ T cells and unconventional T cells including CD1 and $\gamma\delta$ T cells. In general, CD4⁺ T cells help to amplify the host immune response by activating effector cells and recruiting additional immune cells to the site of disease, whereas CD8⁺ T cells are important during the latent stage of TB infection, which act as cytotoxic T cells (CTL) by lysing infected cells (Schluger & Rom, 1998) through production of various cytokines such as IFN- γ and TNF- α . Within a week of infection with virulent *M. tuberculosis*, the number of activated CD4⁺ and CD8⁺ T cells in the lung-draining lymph nodes increases (Feng *et al.*, 1999; Serbina *et al.*, 2000).

Basically, CD4⁺ Th lymphocytes differentiate from precursor Th0 cells under the control of cytokines such as IL-2 and IL-4 into two functionally distinct subsets either type 1 (Th1) or type 2 (Th2) cells (Figure 1.5). Th1 secretes cytokines such as IL-2, IFN- γ , TNF- α and IL-12 resulting in macrophage activation and induction of CMI. In contrast, Th2 secretes IL-4, IL-5, IL-6 and IL-10 resulting in the induction of humoral immunity by antibody production. *M. tuberculosis* resides primarily in a vacuole within the macrophage resulting in major histocompatibility complex (MHC) Class II presentation of mycobacterial antigens to CD4⁺ T cells. The HIV epidemic has demonstrated that the loss of CD4⁺ T cells greatly increases susceptibility of the host to both acute and reactivation TB (reviewed by Flynn, 2004).




Figure 1.5: CD4⁺ T helper lymphocyte subsets upon activation. (Adapted from Cohen *et al.*, 1998).

The other possible roles of CD4⁺ T cells in controlling TB infection include, apoptosis (Keane *et al.*, 1997; Balcwicz-Sablinska *et al.*, 1998), conditioning of antigen presenting cells (APCs), help for B cells and CD8⁺ T cells and production of other cytokines. However, the inability of the CD4⁺ T cells to completely eliminate intracellular bacteria may be due to the lack of recognition or activation of infected macrophages (Flynn, 2004).

CD8⁺ T cells producing IFN- γ probably participate in the activation of macrophages (Caruso *et al.*, 1999; Scanga *et al.*, 2000). CD8⁺ T cells recognize antigens presented by MHC Class I molecules and these antigens are frequently derived from the cytoplasm of the cells. However, *M. tuberculosis* does not reside primarily in the cytoplasm but in vacuoles inside the cells. Studies have suggested that the bacilli within the vacuoles may have access to the cytoplasm, perhaps via a pore in the vacuole's membrane (Teitelbaum *et al.*, 1999). It was suggested that CTL killing of the bacteria depends on their ability to deliver potent bactericidal proteins such as granulysin from their granules (Silva *et al.*, 2001). Lysis of target cells by CD8⁺ T cells can occur via perforin and granzymes or the Fas/FasL (CD95L) pathway resulting in apoptotic cell death or release of bacteria from an infected cell into the granuloma (Canaday *et al.*, 2001). The importance of CD8⁺ T cells in TB was reported by Behar *et al.* (1999), when β 2-microglobulin (β 2-m) and transporter associated protein (TAP1) KO mice, which cannot generate CD8⁺ T cells, were infected with *M. tuberculosis* and resulted in an exacerbated course of infection.

As mentioned earlier, unconventional T cells such as CD1 and $\gamma\delta$ T cells also play a role in host defense against mycobacterial infection. Both cells produce type 1 cytokines, most importantly IFN- γ which activates anti-mycobacterial activities in macrophages (Raupach & Kaufmann, 2001). CD1-restricted $\alpha\beta$ T-lymphocytes are thought to be activated by

mycobacterial lipids (Agger & Andersen, 2002). The CD1 family consists of antigen-presenting molecules encoded by genes located outside of the MHC. CD1 genes are conserved among mammalian species and are expressed on the surface of the cells involved in antigen presentation, notably dendritic cells (DCs). The CD1 system is involved in activation of CMI response against mycobacterial infection. It is the least common T cell subset in human peripheral blood and lung. In humans, most of these T cells express neither CD4 nor CD8 and are referred to as double-negative (DN) cells. In mice, CD1d-restricted natural killer (NK) T cells are activated by mycobacterial cell wall components and are involved in early granuloma formation (Apostolou *et al.*, 1999).

Meanwhile, $\gamma\delta$ T cells are large granular lymphocytes, non-MHC restricted that can develop a dendritic morphology in lymphoid tissues and function as CTL. Unconventional $\gamma\delta$ T cells are activated by small phosphorylated metabolites (Agger & Andersen, 2002). It was suggested that $\gamma\delta$ T cells may play a role in early immune response against TB and is an important part of the protective immunity in patients with latent infection (reviewed by Raja, 2004).

The second process that leads to the initiation of cellular immunity is by costimulation. Antigen presentation only leads to T cell stimulation in the presence of several costimulatory signals. The most well known costimulatory signals for T cell stimulation are B-7.1 (CD80) and B-7.2 (CD86). These molecules are expressed on macrophages and DCs and bind to CD28 and to CTLA-4 on T cells. In the absence of proper costimulatory signals, antigen presentation may lead to an increased apoptosis of T cells (Hirsch *et al.*, 1999 & 2001).

Finally, the production of cytokines may also contribute to the initiation of cellular immunity in TB infection. Several cytokines produced by activated macrophages and DCs are essential for stimulation of T lymphocytes. These include IFN- γ , TNF- α , IL-4, IL-12, IL-18 and IL-15. IFN- γ is produced by T cells from healthy purified protein derivative positive (PPD+) subjects as well as those with active TB. IFN- γ is important to activate macrophage as well as TNF- α that synergize with IFN- γ to induce antimycobacterial effects. Individuals lacking receptors for IFN- γ suffer from recurrent, sometimes lethal mycobacterial infections (Holland *et al.*, 1998). There are three possible cells responsible for nonspecific production of IFN- γ as reviewed by van Crevel *et al.* (2002). First, before adaptive T cell immunity has fully developed, NK cells may be the main producer of IFN- γ , either in response to IL-12 and IL-18 (Iho *et al.*, 1999) or directly by exposure to mycobacterial oligodeoxynucleotides (Garcia *et al.*, 1999). Second, lung macrophages were found to produce IFN- γ in *M. tuberculosis*-infected mice (Wang *et al.*, 1999). Third, the $\gamma\delta$ T cells and CD1-restricted T cells may produce IFN- γ during early infection.

Besides IFN- γ , stimulation of monocytes, macrophages and DCs (Henderson *et al.*, 1997) with mycobacteria or mycobacterial products induce the production of TNF- α . TNF- α plays a role in granuloma formation, induces macrophage activation and has immunoregulatory properties (Orme & Cooper, 1999; Tsenova *et al.*, 1999). In addition to TNF- α , IL-12 has a crucial role in the induction of IFN- γ production (O'Neill & Greene, 1998). IL-12 is produced mainly by phagocytic cells. In TB, IL-12 has been detected in lung infiltrates, in pleurisy, in granulomas and in lymphadenitis (reviewed by van Crevel *et al.*, 2002). The expression of IL-12 receptors is also increased at the site of disease (Zhang *et al.*, 1999). Together with IL-12, IL-18 and IL-15 seem to be important in the IFN- γ axis (O'Neill & Greene, 1998). IL-18 KO mice was found to be highly susceptible to *M. tuberculosis* (Sugawara *et al.*, 1999)

and in mice infected with *M. leprae*, resistance is correlated with a higher expression of IL-18. Moreover, *M. tuberculosis*-mediated production of IL-18 by peripheral blood mononuclear cells (PBMC) is reduced in TB patients and this reduction may be responsible for reduced IFN- γ production (Vankayalapati *et al.*, 2000).

Another cytokine that have been studied regarding TB infection is IL-4. Inhibition of IL-4 production did not seem to promote cellular immunity. IL-4^{-/-} mice displayed normal instead of increased susceptibility to mycobacteria in two studies, suggesting that IL-4 may be a consequence rather than the cause of TB development (Erb *et al.*, 1998; North, 1998).

1.6.3 Humoral Immune Response

Researchers argued about the role of antibodies in host defense against *M. tuberculosis* which was believed that intracellular pathogens cannot be reached by antibodies. However, intracellular pathogens are found in the extracellular space prior to their entry into cells. Furthermore, certain antibodies can enter or mediate biological effects inside cells (reviewed by Glatman-Freedman & Casadevall, 1998). Previous work demonstrated protective effects of antibodies against infection with the intracellular fungus *Cryptococcus neoformans*, as well as other intracellular pathogens (reviewed by Casadevall, 1998). Recently, there are several studies that support the role of antibodies in *M. tuberculosis* infection (Bosio *et al.*, 2000).

M. tuberculosis will infect pulmonary lymph nodes and other organs such as spleen and liver. The dissemination of *M. tuberculosis* probably occurs via entry into alveolar macrophages and via interaction with epithelial cells (Pethe *et al.*, 2001). Heparin binding hemagglutinin adhesion (HBHA) is a surface-exposed glycoprotein involved in the binding

of *M. tuberculosis* to epithelial cells. Administration of *M. bovis* coated with anti-HBHA monoclonal antibodies (mAbs) intranasally reduced colony forming unit (CFU) in the spleen (Petthe *et al.*, 2001) suggesting that anti-HBHA antibodies interfered with mycobacterial dissemination.

Despite playing a role in mycobacterial dissemination, humoral immune response also involved in cytokine expression. A study on the effect of antibodies to PPD on TNF- α expression by monocytes was carried out by Hussain *et al.* (2000). TNF- α is a pro-inflammatory cytokine involved in host response against *M. tuberculosis*, as well as the immunopathology of TB (Engele *et al.*, 2002). TNF- α secretion by PPD-stimulated monocytes from PPD skin test-negative donors was enhanced in the presence of heat-inactivated plasma obtained from patients with pulmonary TB (Hussain *et al.*, 2000). Furthermore, TNF- α secretion directly correlated with plasma concentration of IgG1 to PPD and adsorption of IgG1 from plasma samples led to reduction of TNF- α secretion suggesting a potential role for certain antibody in mediating a biological effect via cytokine release.

Mycobacteria enter the host via the mucosa, therefore antibodies in the secretions could play a role in host defense against mycobacteria. In another study, high titers of antibodies against mycobacteria were observed in mice administered with human gammaglobulin formation and challenged after 2 hours by the intranasal route (Acosta *et al.*, 2003). In addition, mice lungs showed significantly decreased CFU 24 hours after the challenge.

1.7 BCG – the current vaccine

The bacille Calmette-Guerin (BCG) vaccine was named after the French scientists Calmette and Guérin in 1908. They isolated *M. bovis* from a cow with tuberculous mastitis (a common symptom in cattle with bovine TB). They cultured this isolate in a glycerinated, beef/bile/potato medium, subculturing every three weeks for a total of 231 passages, over a period of 13 years. The so-called BCG Pasteur strain was widely distributed throughout the world. As a result, many daughter substrains developed and numerous changes, gene deletions as well as continued passage have attenuated BCG to almost complete avirulence (Behr *et al.*, 1999a; Sabino *et al.*, 2004). A review by Brosch *et al.* (2001), found that there are at least 18 variable regions of difference (RD), representing 120 genes present in *M. tuberculosis* H37Rv but absent in BCG Pasteur. One region, RD1, is missing in all BCG strains but is present in all *M. bovis* and *M. tuberculosis* strain (Mahairas, 1996; Cole *et al.*, 1998; Behr *et al.*, 1999b; Brosch, 2000). This RD1 region might contain some of the genes involved in virulence or regulators of virulence genes. These might account for the phenotypic differences between the vaccine strain and *M. tuberculosis*.

BCG was first tested in infants in 1921 as an oral vaccine. New methods of administration were introduced later, such as intradermal, multiple puncture and scarification. The most widely used BCG vaccine substrains include Connaught, Danish, Glaxo, Moreau, Pasteur and Tokyo (Oettinger *et al.*, 1999). In 1974, BCG vaccination has been included in the WHO Expanded Program on Immunization, resulting in more than three billion doses injected worldwide and approximately 100 million immunizations in children each year. BCG is routinely administered to newborns in countries where TB is endemic and in some lower-incidence countries. A common minor side effect of BCG immunization is the production of induration and ulceration at the vaccination site.